Thyrotropin-secreting pituitary adenoma: a case report.

K Nagai, S Sakata, C C Wu, H Wada, K Yokoyama, M Takada, T Kashiwai, N Tokimitsu
{"title":"Thyrotropin-secreting pituitary adenoma: a case report.","authors":"K Nagai,&nbsp;S Sakata,&nbsp;C C Wu,&nbsp;H Wada,&nbsp;K Yokoyama,&nbsp;M Takada,&nbsp;T Kashiwai,&nbsp;N Tokimitsu","doi":"10.1507/endocrj1954.39.413","DOIUrl":null,"url":null,"abstract":"<p><p>We report a 44-year-old male with a thyrotropin (TSH)-secreting pituitary adenoma. Based serum free triiodothyronine (FT3, 12.1 pmol/l) and free thyroxine (FT4, 28 pmol/l) were increased with normal basal TSH (3.1 mU/l). There was impaired TSH response to thyrotropin releasing hormone (TRH) test. Serum TSH was suppressed to 59% of the basal level after oral administration of 1.4 mg 3,3'-5-triiodothyroacetic acid (triac), whereas no suppression was observed after 75 micrograms daily administration of triiodothyronine (T3). Serum concentrations of alpha-subunit of TSH (TSH-alpha) and TSH-alpha/TSH molar ratio were high, being 1.95 micrograms/l, and 4.4, respectively. Pituitary CT and MRI scan showed the presence of a macroadenoma in the anterior lobe of the pituitary gland. Histopathology of the excised pituitary confirmed the diagnosis of a TSH-producing adenoma. A positive correlation between TSH and FT3 (r = 0.66, P less than 0.01) or FT4 (r = 0.54, P less than 0.01) was observed in serial sera obtained before and after operation.</p>","PeriodicalId":11534,"journal":{"name":"Endocrinologia japonica","volume":"39 4","pages":"413-9"},"PeriodicalIF":0.0000,"publicationDate":"1992-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1507/endocrj1954.39.413","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1507/endocrj1954.39.413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We report a 44-year-old male with a thyrotropin (TSH)-secreting pituitary adenoma. Based serum free triiodothyronine (FT3, 12.1 pmol/l) and free thyroxine (FT4, 28 pmol/l) were increased with normal basal TSH (3.1 mU/l). There was impaired TSH response to thyrotropin releasing hormone (TRH) test. Serum TSH was suppressed to 59% of the basal level after oral administration of 1.4 mg 3,3'-5-triiodothyroacetic acid (triac), whereas no suppression was observed after 75 micrograms daily administration of triiodothyronine (T3). Serum concentrations of alpha-subunit of TSH (TSH-alpha) and TSH-alpha/TSH molar ratio were high, being 1.95 micrograms/l, and 4.4, respectively. Pituitary CT and MRI scan showed the presence of a macroadenoma in the anterior lobe of the pituitary gland. Histopathology of the excised pituitary confirmed the diagnosis of a TSH-producing adenoma. A positive correlation between TSH and FT3 (r = 0.66, P less than 0.01) or FT4 (r = 0.54, P less than 0.01) was observed in serial sera obtained before and after operation.

垂体促甲状腺激素腺瘤1例报告。
我们报告一个44岁男性与促甲状腺激素(TSH)分泌垂体腺瘤。血清游离三碘甲状腺原氨酸(FT3, 12.1 pmol/l)和游离甲状腺素(FT4, 28 pmol/l)升高,基础TSH正常(3.1 mU/l)。促甲状腺激素释放激素(TRH)试验时TSH反应受损。口服1.4 mg 3,3′-5-三碘甲状腺乙酸(triac)后,血清TSH被抑制至基础水平的59%,而每天服用75微克三碘甲状腺原氨酸(T3)后,未观察到抑制。血清中TSH α亚基浓度(TSH- α)和TSH- α /TSH摩尔比较高,分别为1.95微克/l和4.4微克/l。垂体CT和MRI扫描显示垂体前叶有一个大腺瘤。切除垂体的组织病理学证实了tsh产生腺瘤的诊断。术前、术后连续血清TSH与FT3 (r = 0.66, P < 0.01)、FT4 (r = 0.54, P < 0.01)呈正相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信